In a discovery that could reshape how scientists understand the biology of schizophrenia, researchers at the Lieber Institute for Brain Development have produced the first-ever single-cell molecular map of one of the brain’s most enigmatic regions — the habenula.
About the size of a pea, the habenula serves as a hub connecting key brain systems that regulate motivation, mood, and reward — all of which are disrupted in schizophrenia. Yet until now, the habenula has remained largely invisible to human neuroscience.
Published in the American Journal of Psychiatry, the study used single-nucleus RNA sequencing (snRNA-seq) to examine individual brain cells from the habenula of postmortem human tissue. The team identified 17 unique cell populations, including 10 distinct subtypes within the habenula — seven in the lateral and three in the medial region.
Many of these cellular subtypes closely matched those previously seen in rodents, confirming that the habenula’s molecular architecture is conserved across species and offering new confidence that animal models can guide human research.
To understand how these cell types might contribute to schizophrenia, the scientists compared bulk RNA sequencing data from 35 individuals diagnosed with schizophrenia to 33 non-psychiatric controls. They found 173 genes that were expressed differently in schizophrenia — 129 of them unique to the habenula. These genes included known players like NOTCH4 and HES5, which are critical to early brain development, and others linked to dopamine signaling, such as DRD5.
The team also analyzed how genetic risk variants from large-scale genome studies influence gene expression in the habenula. They identified 717 expression quantitative trait loci (eQTLs) and found that 16 overlapped with schizophrenia risk variants. Nine of these had never before been connected to schizophrenia in any other brain region, highlighting the habenula as a previously overlooked contributor to the disorder’s genetic architecture.
"We think this region could be a missing piece in understanding how dopamine and serotonin systems become dysregulated. It may explain why treatments targeting those pathways work for some people but not others.”
A New Frontier in Psychiatric Genomics
The findings reinforce the habenula’s emerging role as a molecular bridge between emotion, cognition, and reward. They also introduce new therapeutic targets that could complement — or even move beyond — the dopamine-centered framework that has dominated schizophrenia research for decades.
By charting this uncharted territory, the Lieber team has provided both a comprehensive atlas of the human habenula and a new window into how complex genetic risk converges on specific neural circuits. The study not only deepens understanding of schizophrenia but also establishes a reference dataset that researchers worldwide can use to explore other mood and addiction-related disorders.
In a field long dominated by studies of the cortex and hippocampus, this work sends a clear message: sometimes the biggest insights come from the brain’s smallest regions.
You may be interested in
We’ve created an accompanying article that focuses on the big picture and real-world impact of this research, without the technical details.
Dr. Maynard leads a Lieber Institute for Brain Development’s laboratory focused on exploring gene expression, brain structure, and brain function in relation to psychiatric diseases. Learn more about her work and the power of high school teachers to spark interest and passion in brain research.